Investment Rating - The report maintains an "Outperform" rating for the company, indicating an expectation of relative performance exceeding the benchmark index by over 10% in the next 12-18 months [1]. Core Insights - The medical aesthetics industry is experiencing a continuous expansion of its consumer base, currently undergoing a reshuffling phase where a few chain brands are expected to capture a larger market share [4]. - The company has a clear development plan for its light medical aesthetics chain, with specific strategies being formulated to establish itself as an industry leader in the foreseeable future [1]. - The stock price of the company is currently undervalued at $3.16, corresponding to a price-to-earnings ratio of only 12 times for its 50 mature stores, with expectations of significant revenue growth [2]. Summary by Sections Industry Trends - The consumer base for medical aesthetics continues to grow, and the industry is in a reshuffling phase, with larger chain brands likely to dominate the market [4]. Company Expansion Plans - The company plans to open over 35 new stores in the upcoming year, primarily focusing on direct-operated stores in major cities like Beijing, Shanghai, Guangzhou, and Shenzhen [4]. - There are already several stores in the opening process, indicating that the company is on track to meet its expansion goals without significant pressure [4]. Store Performance - The average store size is 400 square meters, with mature stores showing excellent profit margins and net profit rates, suggesting strong long-term performance [4]. Competitive Landscape - The current competition is intense, with many standalone institutions lacking advantages in branding, medical teams, supply chains, and location, making it difficult for them to compete with established chains [4]. Product Pipeline - The company is set to launch multiple products next year, including water light injections, youth needles, silk collagen, and extracellular matrix gels, which are expected to enhance its market position [4].

Industry Trends - The medical beauty industry continues to expand, with a consolidation phase where a few chain brands will capture a larger market share[4] - The distribution of industry profits may change as upstream manufacturers undergo similar consolidation, enhancing the pricing power of large downstream institutions[4] Company Performance and Strategy - The current stock price of New Oxygen (SY US) is $3.16, which is considered undervalued, corresponding to a P/E ratio of only 12 times for its 50 mature stores[2] - Management is confident in opening at least 35 new stores in FY2026, primarily focusing on direct-operated stores in major cities like Beijing, Shanghai, Guangzhou, and Shenzhen[4] - In Q3, 20 stores achieved monthly profitability, with mature stores averaging monthly revenue exceeding RMB 3 million[2] Financial Projections - The target price for New Oxygen is set at $10.00 per ADR, based on a Sum-of-the-Parts (SoTP) valuation method, which includes various business segments with different P/E ratios[2] - The retail business is projected to have a steady operating profit margin of 20%, while the medical beauty chain is expected to achieve a 15% steady operating profit margin[2] Competitive Landscape - The competition is intensifying, with most standalone institutions lacking advantages in branding, medical teams, supply chains, and location, making it difficult to compete with chains[4] - New Oxygen is not overly concerned about traditional institutions due to the significant differences in cost structures and operational dimensions[4]

Summary of the Medical Aesthetic Industry Conference Call Industry Overview - The medical aesthetic industry has shown a GMV (Gross Merchandise Volume) growth of 13% year-on-year, reaching 450 million yuan for the period from January to November 2025, although the growth rate has slowed compared to the pandemic period [1][2] - The revenue from the Double Eleven shopping festival accounts for approximately 5% of the total revenue in Q4 [4] Key Insights - **Customer Spending Trends**: - The average transaction value for medical aesthetic products has significantly decreased, with an overall decline of 4% year-on-year. Non-surgical procedures, such as laser treatments and injections, saw a decline of 8-9%, while surgical procedures experienced a stable growth of 2% [1][5] - The long-term trend indicates a continuous decrease in average transaction value, particularly for injection products, which have seen a decline of over 8% [5][6] - **Market Dynamics**: - The decrease in product prices is attributed to increased information transparency, stricter regulations leading to product homogenization, and a rise in new products from upstream manufacturers, which lowers procurement costs [6][7] - Younger consumers are increasingly favoring lower-priced options, and demand from second and third-tier cities has contributed to the decline in average transaction value [6][7] - **Consumer Demographics**: - The proportion of male consumers has increased but remains low at around 5%. The share of younger consumers (ages 18-22) has decreased, while the proportion of consumers aged 35 and above has increased, showing a preference for mid to high-end services and higher repurchase rates [7] - Combined treatments, such as using laser devices alongside injections, have become the norm, reflecting a trend towards package sales [7] Financial Performance - The company has experienced a slowdown in revenue growth, with top-tier institutions reporting a year-on-year revenue increase of about 6% and a net profit margin maintained between 8% and 10% [3][11] - Customer traffic has increased by 12% year-on-year, but the average transaction value has decreased by approximately 5% [11] - The overall revenue growth for the year is expected to be no more than 10%, indicating a shift towards stable growth in the industry [3][11] Competitive Landscape - The market for various medical aesthetic products has become increasingly competitive, with mid-sized and chain clinics experiencing a general slowdown in growth. The overall industry is still growing at over 5%, but the explosive growth phase has ended, leading to a focus on refined operations [13] - The collagen market has seen significant growth, particularly for new specifications introduced by companies to extend product life cycles, despite increased competition from new entrants [19] Inventory Management - Medical aesthetic institutions typically maintain an inventory cycle of about 10 to 15 days, with a slight increase in inventory towards the end of the year to meet peak business demands and supplier requirements [23][24] Conclusion - The medical aesthetic industry is undergoing significant changes, with shifts in consumer behavior, pricing pressures, and competitive dynamics. Companies are adapting their strategies to maintain profitability and market share in a more regulated and competitive environment.

Summary of the Pharmaceutical Industry Conference Call Industry Overview - The pharmaceutical industry is gradually stabilizing and recovering, with most companies optimizing product structures, reducing costs, and benefiting from the recovery in downstream biopharmaceutical demand, leading to profit restoration [1][2][3] - The CRO/CDMO sector shows stable recovery, with revenue and net profit growth of 14% and 36% respectively in the first three quarters [1][6] - The medical device sector is experiencing a turning point, with significant improvements in performance, particularly in the medical equipment segment [1][10] Key Points and Arguments Pharmaceutical Sector Performance - In Q3 2025, the upstream pharmaceutical sector showed signs of recovery, with revenue growth of 2.3% and net profit growth of 55.3% year-on-year [2] - The gross margin for the upstream sector increased by 0.6 percentage points quarter-on-quarter, while sales, management, and R&D expense ratios decreased year-on-year and quarter-on-quarter [2][3] CRO/CDMO Sector - The CRO/CDMO sector's revenue and net profit growth were 14% and 36% respectively, with Q3 profits accelerating compared to Q2 [1][6] - Investment in global biopharmaceuticals has rebounded since 2024, with domestic investment in Q3 2025 increasing by 76% year-on-year and over 150% quarter-on-quarter [1][7] Medical Device Sector - The medical device sector is expected to accelerate in 2026, with the negative impacts of past policies gradually clearing [1][11] - High-value consumables are experiencing differentiation, with some companies showing significant improvement [1][10] Traditional Chinese Medicine - The traditional Chinese medicine sector faced pressure in the first three quarters, but the decline has narrowed, and demand is expected to recover with the arrival of the winter peak season [1][24] Vaccine Industry - The vaccine industry faced significant challenges, with total revenue down 52.5% year-on-year in the first three quarters, but demand for flu vaccines is expected to rise [1][25][26] Blood Products Sector - The blood products sector saw a 1.5% revenue increase but a profit decline of over 20% in the first three quarters, primarily due to pressure on albumin prices [1][31] Retail Pharmacy Sector - The retail pharmacy sector experienced a slight revenue decline but a net profit increase of 16.8% year-on-year in Q3, with expectations for improved customer traffic due to policy changes [1][34][35] Other Important Insights - The medical device sector's performance is expected to improve significantly in 2026, with a focus on performance recovery and valuation opportunities [1][11] - The traditional Chinese medicine sector is anticipated to benefit from adjustments in the basic drug catalog and increased demand in the winter season [1][24] - The CRO/CDMO sector is seeing a positive trend in investment, which is likely to further enhance domestic demand [1][7] - The retail pharmacy sector is expected to benefit from improved customer traffic and a favorable policy environment, leading to potential valuation increases [1][35]

1. Report Industry Investment Rating - The industry rating is "Bullish" [1] 2. Core Views of the Report - The cosmetics industry continues to show differentiation, with brand demand being weak in the off - season, agents seeking change in difficult situations, and producers seizing supply - chain reconstruction opportunities. The medical aesthetics industry has new entrants with better - than - expected shipments, and new product catalysts are worth attention [3][4] 3. Summaries According to Relevant Catalogs 3.1 Cosmetics: Continued Differentiation 3.1.1 Brand Merchants - In 1 - 3Q25, beauty brand merchants' revenue was 28.4 billion yuan, a year - on - year decrease of 0.6%; personal care brand merchants' revenue was 5.7 billion yuan, a year - on - year increase of 12.4%. In 3Q25, beauty and personal care brand merchants' revenues were 8.05 billion and 1.805 billion yuan, a year - on - year decrease of 1.3% and an increase of 7.6% respectively. Beauty revenue weakened quarter - on - quarter, while personal care remained flat [18] - Beauty: Affected by the earlier Double Eleven promotion, consumer enthusiasm declined in September, and brands reduced live - streaming activities. In terms of single - quarter revenue growth, Shuiyang Co., Ltd. and Shanghai Jahwa increased by over 20%, Marubi Co., Ltd. had double - digit growth, Proya had low - double - digit decline, and Betaine and Freda had high - single - digit decline [18] - Personal care: Runben Co., Ltd.'s Q3 revenue increased by 17% year - on - year, with a slight increase in growth rate quarter - on - quarter. Baiya Co., Ltd.'s 3Q25 revenue improved, and Dengkang Oral Care had steady growth [18] - In 1 - 3Q25, beauty brand merchants' net profit after non - recurring items was 2.33 billion yuan, a year - on - year decrease of 15%; personal care brand merchants' was 604 million yuan, a year - on - year decrease of 3.4%. Some companies showed initial cost - control effects [24] 3.1.2 Agents - Agents are seeking change in difficult situations by exploring three paths: incubating self - owned brands (represented by Ruoyuchen), using AI to reduce costs and increase efficiency (represented by Yiwow), and expanding high - growth categories (such as Qingmu Technology expanding into trendy toy agency operations) [30] - Ruoyuchen's self - owned brands Feicui and Zhanjia continued to gain momentum. In Q3, self - owned brand revenue was 451 million yuan, a year - on - year increase of 344.5%, accounting for 55.1%. Zhanjia's Q3 revenue was 227 million yuan, a year - on - year increase of 119%, and 1 - 3Q revenue was 680 million yuan. Feicui's Q3 revenue was 203 million yuan, a quarter - on - quarter increase of over 98.8%, and 1 - 3Q revenue was 362 million yuan [30] 3.1.3 Producers - Demand continued to recover, and the revenue of the producer sector increased by 9%, 17%, and 30% year - on - year from Q1 to Q3, with the growth rate increasing quarter by quarter [33] - QingSong Co., Ltd. focused on optimizing customers and product structure, and its profit turned positive for four consecutive quarters from 2Q24 to 1Q25. Jieya Co., Ltd. had increasing orders from overseas big customers, and its Q3 performance growth accelerated. Jiaheng Home Co., Ltd. increased revenue but not profit, mainly due to the short - term impact of the Huzhou base's capacity ramp - up [33] 3.2 Medical Aesthetics: New Entrants with Better - than - Expected Shipments 3.2.1 Upstream Consumables - The growth rate of demand expansion slowed down, and supply - side competition intensified. In terms of the cumulative number of Class III medical device approvals, hyaluronic acid > regenerative (Sculptra/Poly - L - Lactic Acid) > botulinum toxin > recombinant collagen. Old products of hyaluronic acid and regenerative types faced growth pressure, and the growth rate of recombinant collagen Class III medical device products slowed down significantly quarter - on - quarter [38] - Hyaluronic acid: Aimeike's revenue growth rate from 24Q1 to 25Q3 was + 28.2%/+2.3%/+1.1%/ - 7%/ - 18%/ - 25%/ - 21% year - on - year, showing a quarterly decline since 24Q2 [38] - Collagen: Jinbo Biotech's revenue growth rate from 24Q1 to 25Q1 was + 76%/+100%/+92%/+73%/+63% year - on - year, and in 2Q25/3Q25, it was + 30%/+13% year - on - year. On October 23, the "Recombinant Type I α1 Subtype Collagen Freeze - Dried Fiber" Class III medical device certificate of Giant Biogene was approved by NMPA [38] - Leapmed Medical's medical aesthetics shipments were better than expected, with Q3 medical service and health management business revenue of 320 million yuan, a year - on - year increase of 28%, and the revenue of Sculptra and Hydrodermabrasion reaching 86.1367 million yuan [36] 3.2.2 Downstream - The new model of Xinoxygen Medical Clinics showed high - growth potential. The Q3 revenue guidance was 150 - 170 million yuan, a year - on - year increase of 231% - 275%, and a quarter - on - quarter increase of 4% - 18%. It plans to implement the "100 - City, 1000 - Store" plan in the long term [40] - Stores are expanding from first - tier cities to new first - tier and second - tier cities. As of November 6, it covered 42 stores in 10 cities. The promotion of self - owned brands was remarkable, and it cooperated with Xihong Miracle Sculptra 3.0, priced at 2999 yuan, which was officially launched on September 25 [43] 3.3 Investment Recommendations - Brands with upward potential and both growth and certainty: Recommend Maogeping (Oriental aesthetics, dual - wheel drive of makeup and skincare, and the second - curve of perfume is worth looking forward to) and Shangmei Co., Ltd. (with one cornerstone brand, five growth brands, and N seed businesses) [8][46] - Companies with new product pipelines and expected performance elasticity: Pay attention to Giant Biogene and Leapmed Medical [8][46] - Companies in strategic adjustment and expected to reach an inflection point: Recommend Shuiyang Co., Ltd. (the effect of high - end transformation is gradually emerging), and pay attention to Shanghai Jahwa, Betaine, and Freda [8][46]

Core Insights - The 2025 World Internet Conference held from November 6 to 9 focused on building a collaborative and inclusive digital future, with discussions on AI technology and the digital economy [1] - Jin Xing, founder and CEO of New Oxygen Group, highlighted the transformation of the medical beauty industry from a marketing-driven model to a user experience-centered delivery model, driven by AI and digitalization [1][3] Industry Overview - The Chinese medical beauty market is projected to reach 312 billion yuan in 2024, with a year-on-year growth of 14.8% [3] - The rise of diverse aesthetic values and the "self-appreciation economy" has made medical beauty a representative of new consumption [3] - However, uneven distribution of medical resources and high product prices have led to a trust crisis among consumers [3] Company Strategy - New Oxygen has implemented vertical integration and cost structure optimization since 2021, enhancing the safety, quality consistency, and inclusiveness of medical beauty services through digitalization and AI [3][4] - The company has established standardized fulfillment and dynamic quality control mechanisms to unify service quality across its stores [4][5] - New Oxygen has opened 41 stores in 10 major cities, becoming the largest chain in the light medical beauty sector in China [3] AI and Digitalization - New Oxygen has explored various AI applications in medical beauty, including intelligent skin detection and cross-regional store management, with five AI algorithms registered with the National Internet Information Office [7][8] - The company faces challenges in deep AI application due to high costs and the need for extensive multimodal data [8] - Jin Xing emphasized the importance of overcoming technical challenges to expand AI applications in the medical beauty sector [8] Pricing and Consumer Trust - The average customer price for light medical beauty in China is approximately 3,146 yuan, which is nearly equal to the average monthly disposable income [10] - High prices have contributed to the rise of "black medical beauty," creating potential medical risks [10] - New Oxygen aims to reduce marketing and supply chain costs from 60-80% to below 20% through vertical integration and digital operations, establishing a transparent pricing system [10] Regulatory Environment - Recent government policies are accelerating changes in the medical beauty pricing system, with efforts to streamline clinical trial approval processes [11] - The approval of various popular medical beauty products is expected to shift the market from a seller's market to a buyer's market, enhancing consumer trust [11] - New Oxygen is committed to maintaining transparency and quality in its services while expanding its store network [11]

Summary of the Conference Call for Sihuan Pharmaceutical Industry Overview - Sihuan Pharmaceutical has been expanding into the medical aesthetics sector since 2014, starting with the Korean botulinum toxin product, Letibotulinum, which was approved for sale in China in 2020. The revenue from this product is expected to reach nearly 1 billion yuan by 2025, accounting for 80% of the medical aesthetics business [2][3][4]. Key Points and Arguments - **Revenue Growth**: In the first half of the year, Sihuan Pharmaceutical achieved revenue of 585 million yuan, representing a year-on-year growth of 81%. The company anticipates a full-year growth of no less than 50% [2][3]. - **Product Launches**: The company has introduced self-developed products such as the "Youthful Needle," "Girl Needle," and "Water Light Energy Serum," which are expected to contribute significantly to revenue [2][3]. - **Market Coverage**: Sihuan Pharmaceutical has established a strong market presence, covering over 7,000 medical aesthetic institutions and achieving 100% coverage with 500 leading institutions. Additionally, strategic cooperation agreements have been signed with 1,400 key institutions [2][3]. - **Production Capacity**: The company operates three production bases to ensure product quality and currently sells six major products, including botulinum toxin, hyaluronic acid, and self-developed products [2][4]. - **Research and Development**: Sihuan Pharmaceutical has built five major R&D platforms, covering international innovative materials and regenerative materials, with over 60 medical aesthetic products in its portfolio. The company conducts hundreds of medical training sessions and market activities annually to enhance academic promotion [2][4]. - **Financial Position**: The company has approximately 3.9 billion yuan in cash, indicating strong financial resources to support future growth [2][4]. Competitive Landscape - **Botulinum Toxin Market**: Letibotulinum currently accounts for about 80% of Sihuan Pharmaceutical's medical aesthetics revenue. As new self-developed products are launched, this proportion is expected to decrease. Letibotulinum is the first Korean botulinum toxin brand approved in China and has maintained a leading position due to its suitability for Asian skin [3][4]. - **Market Penetration**: The domestic botulinum toxin market has low penetration rates, but the company believes that increased competition will drive growth in market penetration. The safety and affordability of botulinum toxin are expected to attract more consumers [4][5]. Product Differentiation - **Hyaluronic Acid Product**: The company’s hyaluronic acid product, "Bohuanrun," utilizes HEXALINK™ unidirectional cross-linking technology, enhancing its resistance to pressure and deformation, with a stable shaping effect lasting up to one year. It is positioned competitively in a crowded market [6]. - **Comprehensive Product Line**: Sihuan Pharmaceutical offers a wide range of products, including injectables, fillers, water light needles, collagen, and silk protein, establishing a comprehensive product layout [7]. Unique Selling Proposition - **CDK 4/6 Inhibitor**: The company’s CDK 4/6 inhibitor is the first and only approved drug for monotherapy in the domestic market, with low toxicity and broad indications. The company plans to leverage its unique characteristics and clinical performance to maximize market potential [8][9]. Future Outlook - **Revenue Targets**: Sihuan Pharmaceutical aims to achieve over 1 billion yuan in revenue from existing products and 200 million yuan from new products by 2025, with total revenue reaching 1.2 billion yuan. The company expects to maintain an annual growth rate of no less than 50% over the next two to three years [2][4][12].

Investment Rating - The report maintains an "Outperform" rating for the company, with a target price of RMB 75.81 based on a 2025 PS of 11X [4][10]. Core Insights - The company achieved revenue of RMB 1.87 billion in the first three quarters of 2025, showing a slight decrease of 0.01% year-on-year, while net profit attributable to shareholders improved, reducing losses by RMB 343 million to RMB -120 million [4][10]. - As of September 30, 2025, the company had cash reserves of RMB 2.19 billion, a decrease of RMB 427 million from June 30, 2025 [4][10]. - In Q3 2025, the company reported revenue of RMB 755 million, reflecting a growth of 14.45% year-on-year, with net profit attributable to shareholders at RMB -16 million, indicating continued loss reduction [4][11]. - The company effectively controlled its expense ratios, with a gross profit margin of 54.01% (down 4.37 percentage points), and reductions in sales, general and administrative, and R&D expense ratios [4][12]. - The company holds a significant number of patents, with 640 domestic and 492 foreign effective patents, totaling 1,132 effective authorized patents as of September 30, 2025 [4][13]. Financial Summary - Total revenue projections for the upcoming years are as follows: RMB 2.87 billion in 2025, RMB 3.33 billion in 2026, and RMB 3.78 billion in 2027, with respective growth rates of -4.7%, 16.1%, and 13.5% [3]. - The net profit attributable to shareholders is projected to improve significantly from RMB -146 million in 2025 to RMB 151 million in 2027, reflecting a growth rate of 1,538.4% [3]. - The company’s return on equity (ROE) is expected to turn positive by 2027, reaching 1.9% [3].

Core Viewpoint - Aimeike, known as "the Moutai for women," is experiencing a significant decline in its business performance, with both revenue and net profit dropping sharply in recent quarters [1][5][10]. Financial Performance - In the first three quarters of 2025, Aimeike reported revenue exceeding 1.86 billion yuan, a year-on-year decrease of over 21%, and a net profit of nearly 1.1 billion yuan, down over 30% [1][5]. - This marks the first time in nearly a decade that Aimeike has experienced a decline in both revenue and net profit over three quarters [2][8]. - The company has seen a continuous decline in performance for four consecutive quarters, with no signs of recovery [2][8]. Product Performance - Aimeike's core products have lost market share, with revenue from its two main products declining in the first half of 2025 [3][11]. - The acquisition of the "童颜针" (Youth Needle) for nearly 1.4 billion yuan has not yet shown positive results in the company's financials [3][12]. - The revenue contribution from Aimeike's main products, including "嗨体" and "濡白天使," has decreased significantly, dropping from 98.57% in 2023 to 95.24% in the first half of 2025 [11][12]. Market Competition - The medical aesthetics industry is facing intensified competition, leading to squeezed profit margins for Aimeike [10][11]. - The market is shifting from expansion to value reconstruction, with a notable increase in competition from new entrants and evolving consumer demands [10][11]. - Aimeike's main products, which include gel and solution injection products, are facing challenges from competitors like 华熙生物 and 圣博玛, which have introduced similar products to the market [11][12]. Historical Context - Aimeike's revenue and net profit had been growing rapidly from 2016 to 2023, with revenue increasing from 141 million yuan to 2.87 billion yuan and net profit from 53 million yuan to 1.86 billion yuan during the same period [5][6]. - The company experienced a slowdown in growth starting in 2024, with revenue and net profit growth rates falling to single digits for the first time since 2016 [6][10].

Investment Rating - The report maintains an "Outperform" rating for the company [4][12][26]. Core Insights - The company has shown stable overall performance, with explosive growth in new products such as "童颜针" (Youth Needle) and "水光针" (Water Light Needle), driving rapid profit growth [1][4]. - In the first three quarters of 2025, the company achieved revenue of RMB 4.94 billion, a year-on-year increase of 3.20%, and a net profit attributable to shareholders of RMB 982 million, up 22.35% [4][12]. - The target price is set at RMB 20.29, based on a PE ratio of 35X for 2025, reflecting the company's stable growth and rapid expansion of new products [4][12]. Financial Summary - Total revenue for 2023 is projected at RMB 7.98 billion, with a decrease of 24.8% compared to the previous year. However, revenue is expected to grow by 10.1% in 2025 and continue to rise in subsequent years [3][5]. - Net profit attributable to shareholders is forecasted to be RMB 1.09 billion in 2025, a significant increase of 341.5% from 2024 [3][5]. - The company reported a net cash flow from operating activities of RMB 1.01 billion, reflecting a substantial increase of 139.37% [4][12]. Product Performance - In Q3 2025, the company generated revenue of RMB 1.57 billion, with specific products like "童颜针" and "水光针" contributing RMB 86.14 million for the first time [4][13]. - The cardiovascular intervention segment remains the largest revenue contributor, generating RMB 1.79 billion, up 7.45% year-on-year [4][15]. - The medical services and health management segment also showed growth, with revenue reaching RMB 796 million, an increase of 6.79% [4][15].